Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 over exp |
Therapy | Pembrolizumab |
Indication/Tumor Type | chondrosarcoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 over exp | chondrosarcoma | predicted - sensitive | Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical case study, Keytruda (pembrolizumab) treatment resulted in a complete response lasting 24 months in a patient with CD274 (PD-L1)-positive (95%) metastatic dedifferentiated chondrosarcoma also harboring NRAS G13R (PMID: 36465334). | 36465334 |
PubMed Id | Reference Title | Details |
---|---|---|
(36465334) | Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response. | Full reference... |